{
    "Trade/Device Name(s)": [
        "DiaSorin LIAISON\u00ae Rubella IgG Assay",
        "DiaSorin LIAISON\u00ae Rubella IgG Tri-Controls",
        "Rubella IgG Test Reagents and Controls",
        "LIAISON\u00ae Rubella IgG",
        "LIAISON\u00ae Rubella IgG Tri-Control kit"
    ],
    "Submitter Information": "DiaSorin, Inc.",
    "510(k) Number": "K073390",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003412"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFX",
        "JJX"
    ],
    "Summary Letter Date": "January 11, 2013",
    "Summary Letter Received Date": "November 12, 2008",
    "Submission Date": "November 10, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3510"
    ],
    "Regulation Name(s)": [
        "Rubella Virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology",
        "immunology"
    ],
    "Analyte(s)": [
        "Rubella IgG antibody"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect immunoassay"
    ],
    "Methodologies": [
        "Indirect chemiluminescence immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Quality control material",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Rubella IgG CLIA for detection of rubella immunity status using LIAISON Analyzer",
    "Indications for Use Summary": "Qualitative determination of IgG antibodies to rubella virus in human serum to aid in immune status determination, including for pregnant women; Tri-Control kit for quality control monitoring of the assay",
    "fda_folder": "Microbiology"
}